Lannett Advances Its Insulin Glargine

Rival To Sanofi’s Lantus Gets Positive Feedback From FDA

 
• By Akriti Seth
  
Road
Lannett will file a 351(k) biosimilar application by 2022 • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products